GT
LUMO

Glenmede Trust’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Glenmede Trust’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-961
Closed -$157K – 2729
2016
Q1 		$157K Buy
+961
New +$195K ﹤0.01% 1226

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Glenmede Trust's LUMO Position: Q2 2016 in Review

Glenmede Trust sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2016, closing a stake of 961 shares — an estimated $157K sold.

Glenmede Trust first reported a position in LUMO in Q1 2016 and held it in 1 quarter. The position peaked at $157K in Q1 2016. 112 funds tracked by Wall St. Rank hold LUMO as of Q2 2016.

  • Glenmede Trust reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Glenmede Trust sold 961 Lumos Pharma, Inc. Common Stock shares in Q2 2016, an estimated $157K.
  • Glenmede Trust first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • Glenmede Trust's Lumos Pharma, Inc. Common Stock position peaked at $157K in Q1 2016.
  • 112 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.